Clinical Trial Detail

NCT ID NCT04039607
Title A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

hepatocellular carcinoma

Therapies

Lenvatinib

Sorafenib

Ipilimumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.